Nature Medicine (journal)

August 1, 2025

Study reports final clinical trial data for advanced kidney cancer treatment

The drug combo pembrolizumab plus axitinib had sustained and durable clinical benefit in more than five years of follow-up. It is a standard-of-care first-line treatment for advanced kidney cancer.

By Leigh MacMillan
(Adobe Stock)
July 24, 2024

Study links low-quality sleep with chronic disease

The research shows that by getting enough sleep and reducing variability around sleep onset and wake times, patients can reduce the incidence of chronic disease.

By Matt Batcheldor
June 25, 2024

Gene variant may underlie diabetes disparities: study

The study was the largest ancestry-stratified, genetic estimation of the heritability of diabetic retinopathy conducted to date and included an unprecedented number of individuals of non-Hispanic African ancestry — more than 46,000.

By Bill Snyder
June 12, 2024

Study shows a simple blood test can predict cardiorespiratory fitness

The researchers tested the feasibility of using a simple set of proteins from blood to capture a molecular fingerprint of cardiorespiratory fitness.

By Matt Batcheldor
March 7, 2024

Blood mutations increase risk for acute kidney injury: study

A U.S.-Canadian research collaboration led by Vanderbilt University Medical Center has identified common, age-associated changes in the blood as a risk factor for acute kidney injury, which occurs in more than 1 in 5 hospitalized adults worldwide.

By Bill Snyder
February 19, 2024

VUMC part of major step to achieving precision medicine

An analysis of genomic data from nearly 250,000 participants in the National Institutes of Health’s All of Us Research Program has identified more than 275 million previously unreported genetic variations, nearly 4 million of which have potential health consequences.

By Bill Snyder
October 17, 2023

Tirzepatide trial shows additional 21.1% weight loss following intensive lifestyle intervention

A Vanderbilt clinical trial evaluating the injectable prescription medication tirzepatide, showed an additional 21.1% weight loss after intensive lifestyle intervention in adults with obesity or who were overweight with weight-related comorbidities, excluding Type 2 diabetes.
By Jill Clendening
September 28, 2023

Drug trial shows reduced abnormal bone formation in those with fibrodysplasia ossificans progressiva

A Vanderbilt clinical trial evaluating the investigational drug garetosmab has shown that it reduced soft-tissue flare-ups significantly and prevented new areas of abnormal bone formation in patients with fibrodysplasia ossificans progressiva.
By Jill Clendening
July 7, 2023

Rett syndrome drug studied at Vanderbilt approved for patients

The first drug to treat the symptoms of Rett syndrome was recently approved, following a Nature Medicine study publishing results from the pivotal phase 3 LAVENDER study led by investigators from Vanderbilt University Medical Center to evaluate efficacy and safety of trofinetide.
By Craig Boerner
October 10, 2022

Counting steps can reduce disease risk: study

A Vanderbilt study found that using a wearable activity tracker to count and increase the number and intensity of steps taken daily can reduce the risk of several common, chronic diseases.
By Bill Snyder
March 7, 2022

Study finds World Trade Center responders at higher risk for blood cancer-associated mutations

A study by Vanderbilt and New York City researchers found that 9/11 first responders to the World Trade Center have increased levels of mutations that escalate their risk for blood cancers or cardiovascular disease
By Tom Wilemon
June 3, 2021

Predictive model identifies patients for genetic testing

Patients who, perhaps unbeknownst to their health care providers, are in need of genetic testing for rare undiagnosed diseases can be identified en masse based on routine information in electronic health records (EHRs), a research team reported June 3 in the journal Nature Medicine.
By Paul Govern
March 4, 2021

Monoclonal antibody “cocktail” blocks COVID-19 variants: study

A monoclonal antibody “cocktail” developed at Vanderbilt University Medical Center to neutralize the COVID-19 virus is effective against all known strains, or variants, of the virus, according to a report published today in the journal Nature Medicine.
By Bill Snyder
1 2 3